Loading…
The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners
Chronic hepatitis C virus infection has a widespread presence in the world’s population. Because of its potential for liver decompensation and secondary manifestations, hepatitis C virus has been the subject of many clinical trials over the past 20 years. This article will delineate the results of t...
Saved in:
| Published in: | Journal for nurse practitioners 2015-01, Vol.11 (1), p.116-123 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c400t-739c75bc5d52feeef7bb7ec5ad7ee5adf6757f582616cd865eb5bcd0008fbe1d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c400t-739c75bc5d52feeef7bb7ec5ad7ee5adf6757f582616cd865eb5bcd0008fbe1d3 |
| container_end_page | 123 |
| container_issue | 1 |
| container_start_page | 116 |
| container_title | Journal for nurse practitioners |
| container_volume | 11 |
| creator | Olson, Mary C. Gardenier, Donald Jacobson, Ira M. |
| description | Chronic hepatitis C virus infection has a widespread presence in the world’s population. Because of its potential for liver decompensation and secondary manifestations, hepatitis C virus has been the subject of many clinical trials over the past 20 years. This article will delineate the results of these various studies. The interferon-free regimens with combinations of all oral antiviral combinations will provide improved tolerability and efficacy with sustained viral response rates greater than 90%. The outcomes and the commonly accepted methodologies for treatment, according to patient requirements, will be provided for the primary care nurse practitioner.
•Revolution of Hepatitis C treatment from interferon based regimens to all oral interferon free regimens.•Review of pivotal clinical trial data for new Direct Acting Antiviral Regimens for HCV with SVR rates >90%.•Implications for the Primary Care Nurse Practitioner. |
| doi_str_mv | 10.1016/j.nurpra.2014.10.013 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1755540424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1555415514006916</els_id><sourcerecordid>1755540424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-739c75bc5d52feeef7bb7ec5ad7ee5adf6757f582616cd865eb5bcd0008fbe1d3</originalsourceid><addsrcrecordid>eNqFkU1LxDAQhoMouK7-Aw8FL15akzYf1YMgi7qCqMgK3kKbTjCl29QkVfz3ptSTB73MDC_PDDPzInRMcEYw4Wdt1o9ucFWWY0KjlGFS7KAFKUWZYla-7saaMZbSGPfRgfctxkXJC7pA680bJM_wYbsxGNsnVidrGKpggvHJKtk4qMIW-uAvJsrAZ6KtSx5G5yF5cpWaQNuD84doT1edh6OfvEQvN9eb1Tq9f7y9W13dp4piHFJRnCvBasUalmsA0KKuBShWNQIgRs0FE5qVOSdcNSVnUEe6wRiXugbSFEt0Os8dnH0fwQe5NV5B11U92NFLIuKlFNOc_o9yRrkoijKP6MkvtLWj6-MhkaJk2obwSNGZUs5670DLwZlt5b4kwXJyQrZydkJOTkxqdCK2Xc5tEP8Sf-ikVwZ6BY1xoIJsrPl7wDch7pPM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1641261616</pqid></control><display><type>article</type><title>The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Social Science Premium Collection</source><source>ScienceDirect Journals</source><source>Sociology Collection</source><creator>Olson, Mary C. ; Gardenier, Donald ; Jacobson, Ira M.</creator><creatorcontrib>Olson, Mary C. ; Gardenier, Donald ; Jacobson, Ira M.</creatorcontrib><description>Chronic hepatitis C virus infection has a widespread presence in the world’s population. Because of its potential for liver decompensation and secondary manifestations, hepatitis C virus has been the subject of many clinical trials over the past 20 years. This article will delineate the results of these various studies. The interferon-free regimens with combinations of all oral antiviral combinations will provide improved tolerability and efficacy with sustained viral response rates greater than 90%. The outcomes and the commonly accepted methodologies for treatment, according to patient requirements, will be provided for the primary care nurse practitioner.
•Revolution of Hepatitis C treatment from interferon based regimens to all oral interferon free regimens.•Review of pivotal clinical trial data for new Direct Acting Antiviral Regimens for HCV with SVR rates >90%.•Implications for the Primary Care Nurse Practitioner.</description><identifier>ISSN: 1555-4155</identifier><identifier>EISSN: 1878-058X</identifier><identifier>DOI: 10.1016/j.nurpra.2014.10.013</identifier><language>eng</language><publisher>Philadelphia: Elsevier Inc</publisher><subject>cirrhosis ; Diabetes ; direct-acting antiviral ; Drug dosages ; FDA approval ; Genomes ; Genotype & phenotype ; Hepatitis ; Hepatitis C ; Hepatitis C virus ; HIV ; Human immunodeficiency virus ; Infections ; Interferon ; interferon free ; Liver cancer ; Liver cirrhosis ; liver disease ; Liver diseases ; nurse practitioner ; Proteins ; Response rates ; RNA polymerase ; treatment experienced ; treatment naive</subject><ispartof>Journal for nurse practitioners, 2015-01, Vol.11 (1), p.116-123</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright Elsevier Limited Jan 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-739c75bc5d52feeef7bb7ec5ad7ee5adf6757f582616cd865eb5bcd0008fbe1d3</citedby><cites>FETCH-LOGICAL-c400t-739c75bc5d52feeef7bb7ec5ad7ee5adf6757f582616cd865eb5bcd0008fbe1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1641261616/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1641261616?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>313,314,777,781,789,12827,21375,21376,27903,27905,27906,30980,33592,33593,34511,34512,43714,44096,73970,74388</link.rule.ids></links><search><creatorcontrib>Olson, Mary C.</creatorcontrib><creatorcontrib>Gardenier, Donald</creatorcontrib><creatorcontrib>Jacobson, Ira M.</creatorcontrib><title>The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners</title><title>Journal for nurse practitioners</title><description>Chronic hepatitis C virus infection has a widespread presence in the world’s population. Because of its potential for liver decompensation and secondary manifestations, hepatitis C virus has been the subject of many clinical trials over the past 20 years. This article will delineate the results of these various studies. The interferon-free regimens with combinations of all oral antiviral combinations will provide improved tolerability and efficacy with sustained viral response rates greater than 90%. The outcomes and the commonly accepted methodologies for treatment, according to patient requirements, will be provided for the primary care nurse practitioner.
•Revolution of Hepatitis C treatment from interferon based regimens to all oral interferon free regimens.•Review of pivotal clinical trial data for new Direct Acting Antiviral Regimens for HCV with SVR rates >90%.•Implications for the Primary Care Nurse Practitioner.</description><subject>cirrhosis</subject><subject>Diabetes</subject><subject>direct-acting antiviral</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Genomes</subject><subject>Genotype & phenotype</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Infections</subject><subject>Interferon</subject><subject>interferon free</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>liver disease</subject><subject>Liver diseases</subject><subject>nurse practitioner</subject><subject>Proteins</subject><subject>Response rates</subject><subject>RNA polymerase</subject><subject>treatment experienced</subject><subject>treatment naive</subject><issn>1555-4155</issn><issn>1878-058X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>ALSLI</sourceid><sourceid>HEHIP</sourceid><sourceid>M2S</sourceid><recordid>eNqFkU1LxDAQhoMouK7-Aw8FL15akzYf1YMgi7qCqMgK3kKbTjCl29QkVfz3ptSTB73MDC_PDDPzInRMcEYw4Wdt1o9ucFWWY0KjlGFS7KAFKUWZYla-7saaMZbSGPfRgfctxkXJC7pA680bJM_wYbsxGNsnVidrGKpggvHJKtk4qMIW-uAvJsrAZ6KtSx5G5yF5cpWaQNuD84doT1edh6OfvEQvN9eb1Tq9f7y9W13dp4piHFJRnCvBasUalmsA0KKuBShWNQIgRs0FE5qVOSdcNSVnUEe6wRiXugbSFEt0Os8dnH0fwQe5NV5B11U92NFLIuKlFNOc_o9yRrkoijKP6MkvtLWj6-MhkaJk2obwSNGZUs5670DLwZlt5b4kwXJyQrZydkJOTkxqdCK2Xc5tEP8Sf-ikVwZ6BY1xoIJsrPl7wDch7pPM</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Olson, Mary C.</creator><creator>Gardenier, Donald</creator><creator>Jacobson, Ira M.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ASE</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HEHIP</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201501</creationdate><title>The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners</title><author>Olson, Mary C. ; Gardenier, Donald ; Jacobson, Ira M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-739c75bc5d52feeef7bb7ec5ad7ee5adf6757f582616cd865eb5bcd0008fbe1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>cirrhosis</topic><topic>Diabetes</topic><topic>direct-acting antiviral</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Genomes</topic><topic>Genotype & phenotype</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Infections</topic><topic>Interferon</topic><topic>interferon free</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>liver disease</topic><topic>Liver diseases</topic><topic>nurse practitioner</topic><topic>Proteins</topic><topic>Response rates</topic><topic>RNA polymerase</topic><topic>treatment experienced</topic><topic>treatment naive</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olson, Mary C.</creatorcontrib><creatorcontrib>Gardenier, Donald</creatorcontrib><creatorcontrib>Jacobson, Ira M.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Sociology Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal for nurse practitioners</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olson, Mary C.</au><au>Gardenier, Donald</au><au>Jacobson, Ira M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners</atitle><jtitle>Journal for nurse practitioners</jtitle><date>2015-01</date><risdate>2015</risdate><volume>11</volume><issue>1</issue><spage>116</spage><epage>123</epage><pages>116-123</pages><issn>1555-4155</issn><eissn>1878-058X</eissn><abstract>Chronic hepatitis C virus infection has a widespread presence in the world’s population. Because of its potential for liver decompensation and secondary manifestations, hepatitis C virus has been the subject of many clinical trials over the past 20 years. This article will delineate the results of these various studies. The interferon-free regimens with combinations of all oral antiviral combinations will provide improved tolerability and efficacy with sustained viral response rates greater than 90%. The outcomes and the commonly accepted methodologies for treatment, according to patient requirements, will be provided for the primary care nurse practitioner.
•Revolution of Hepatitis C treatment from interferon based regimens to all oral interferon free regimens.•Review of pivotal clinical trial data for new Direct Acting Antiviral Regimens for HCV with SVR rates >90%.•Implications for the Primary Care Nurse Practitioner.</abstract><cop>Philadelphia</cop><pub>Elsevier Inc</pub><doi>10.1016/j.nurpra.2014.10.013</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1555-4155 |
| ispartof | Journal for nurse practitioners, 2015-01, Vol.11 (1), p.116-123 |
| issn | 1555-4155 1878-058X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1755540424 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); Social Science Premium Collection; ScienceDirect Journals; Sociology Collection |
| subjects | cirrhosis Diabetes direct-acting antiviral Drug dosages FDA approval Genomes Genotype & phenotype Hepatitis Hepatitis C Hepatitis C virus HIV Human immunodeficiency virus Infections Interferon interferon free Liver cancer Liver cirrhosis liver disease Liver diseases nurse practitioner Proteins Response rates RNA polymerase treatment experienced treatment naive |
| title | The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A48%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Revolution%20of%20Hepatitis%20C%20Treatments:%20Review%20for%20Nurse%20Practitioners&rft.jtitle=Journal%20for%20nurse%20practitioners&rft.au=Olson,%20Mary%20C.&rft.date=2015-01&rft.volume=11&rft.issue=1&rft.spage=116&rft.epage=123&rft.pages=116-123&rft.issn=1555-4155&rft.eissn=1878-058X&rft_id=info:doi/10.1016/j.nurpra.2014.10.013&rft_dat=%3Cproquest_cross%3E1755540424%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-739c75bc5d52feeef7bb7ec5ad7ee5adf6757f582616cd865eb5bcd0008fbe1d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1641261616&rft_id=info:pmid/&rfr_iscdi=true |